13 C]leucine-labeled protein with (PRONO3) or without (PRO) sodium nitrate (0.15 mmol/kg). Blood and muscle samples were collected to assess protein digestion and absorption kinetics and postprandial muscle protein synthesis rates. Upon protein ingestion, exogenous phenylalanine appearance rates increased in both groups (P Ͻ 0.001), resulting in 55 Ϯ 2% and 53 Ϯ 2% of dietary protein-derived amino acids becoming available in the circulation over the 5h postprandial period in the PRO and PRONO3 groups, respectively. Postprandial myofibrillar protein synthesis rates based on L-[ring-2 H5]phenylalanine did not differ between groups (0.025 Ϯ 0.004 and 0.021 Ϯ 0.007%/h over 0 -2 h and 0.032 Ϯ 0.004 and 0.030 Ϯ 0.003%/h over 2-5 h in PRO and PRONO3, respectively, P ϭ 0.7). No differences in incorporation of dietary protein-derived L-[1-
dietary nitrate; protein ingestion; aging; type 2 diabetes; anabolic resistance AGING IS ASSOCIATED with loss of skeletal muscle mass and strength, termed sarcopenia, and results in loss of functional capacity, a higher risk for hospitalization, and development of chronic metabolic diseases (33) . Recently, we (20, 31) , as well as others (25, 35) , showed that sarcopenia is more pronounced in older individuals with type 2 diabetes than in age-matched, normoglycemic controls. Since skeletal muscle tissue is a large site of postprandial glucose disposal, it is evident that the age-related loss of skeletal muscle mass is often accompanied by an insulin-resistant state (20, 31, 35) .
Maintenance of skeletal muscle mass is regulated by muscle protein synthesis and muscle protein breakdown rates. A chronic imbalance between muscle protein synthesis and muscle protein breakdown rates contributes to the accelerated loss of skeletal muscle mass with aging. It has been well established that protein ingestion and the associated increase in postprandial plasma amino acids in the circulation directly increase muscle protein synthesis rates (15, 26, 34, 50) . However, the postprandial stimulation of muscle protein synthesis following protein intake is impaired with aging, a phenomenon commonly referred to as anabolic resistance (15) . This anabolic resistance to protein intake is considered to be a key factor in the progressive loss of skeletal muscle mass with aging. Although the factor(s) underpinning anabolic resistance remains unclear, age-related impairments in endothelium-dependent vasodilation and blood flow in response to nutrient (32) and exercise (19) stimuli are suggested to play a key role.
The postprandial muscle protein synthetic response to protein feeding is regulated by numerous factors, such as protein digestion and amino acid absorption, amino acid availability in the circulation, delivery to skeletal muscle tissue, and uptake in the muscle (9) . The postprandial increase in muscle microvascular perfusion facilitates the delivery of amino acids, nutrients, and growth factors to the muscle, thereby allowing muscle protein synthesis rates to increase after protein ingestion (43, 49). However, aging and insulin resistance are associated with reduced skeletal muscle capillary density, impaired endothelial function, and reduced nitric oxide (NO) availability (14, 20, 32, 39, 40) . As such, age-related impairments in vascular function due to an impaired NO-mediated vasodilatory response and decreased muscle tissue perfusion may diminish feeding-mediated increases in muscle protein synthesis and, thus, contribute to the anabolic resistance of aging (7, 24) .
It has been reported that dietary nitrate (NO 3 Ϫ ) supplementation, via sequential reduction of NO 3 Ϫ to nitrite (NO 2 Ϫ ) and NO, can stimulate NO synthesis and increase NO bioavailability (55) . Moreover, it has been suggested that NO has a role in promoting insulin delivery to skeletal muscle tissue and increasing insulin-stimulated muscle perfusion and capillary action (22, 51) . As such, ingestion of a single dose of dietary NO 3 Ϫ might increase endothelial NO availability, thereby increasing blood flow and tissue perfusion and the subsequent muscle anabolic response to food intake. Recently, the acute ingestion of NO 3 Ϫ -rich dietary sources has been shown to improve vascular function (21, 23, 29, 53 ) and macro-and microvascular blood flow (3, 29) in healthy subjects, as well as in overweight individuals and diabetes patients. In support of these findings, pharmacological increases in blood flow and tissue perfusion following administration of a NO-donating vasodilator, sodium nitroprusside, combined with amino acid provision have been shown to increase postprandial muscle protein synthesis rates in older subjects (17) . However, whether dietary NO 3 Ϫ co-ingestion with a protein meal can be used as a nutritional strategy to augment the postprandial muscle protein synthetic response remains to be assessed.
In particular, dietary NO 3 Ϫ may serve as an effective nutritional strategy to counteract the age-related anabolic resistance of muscle protein synthesis to protein ingestion through NOmediated increases in skeletal muscle microvascular perfusion. In the current investigation we hypothesized that a single dose of dietary NO 3 Ϫ co-ingested with protein increases amino acid delivery to skeletal muscle tissue and, subsequently, enhances the postprandial muscle protein synthetic response.
METHODS
Subjects. Twenty-four older (72 Ϯ 1 yr), type 2 diabetes patients (body mass index ϭ 26.7 Ϯ 1.4 m/kg 2 , HbA1C ϭ 7.3 Ϯ 0.4%) were randomly assigned to two groups: a group that ingested protein with NaCl (PRO) or a group that ingested protein with NaNO 3 Ϫ (PRONO3). Subjects' characteristics are presented in Table 1 . All subjects were using oral blood glucose-lowering medication and continued their habitual medication. Diabetes patients had been diagnosed with type 2 diabetes 2-18 yr prior to screening. One subject in the PRO group was unable to complete the trial and was, therefore, excluded from analysis. Subjects were informed of the nature and possible risks of the experimental procedures prior to providing written informed consent. The trial, conducted between August 2011 and July 2012 at Maastricht University, was part of a larger project investigating the impact of protein feeding on muscle metabolism in older, type 2 diabetes patients (28) . The study was approved by the Medical Ethical Committee of the Maastricht University Medical Centre and conformed to standards for the use of human subjects in research as outlined in the latest version of the Declaration of Helsinki.
Pretesting. All subjects participated in a prescreening session to assess their HbA 1C, glucose tolerance [by a 2-h oral glucose tolerance test (2) ], blood pressure, weight, height, and body composition [by dual-energy X-ray absorptiometry (Discovery A, Hologic, Bedford, MA)]. The subjects were deemed healthy on the basis of their responses to a medical questionnaire and screening results. All subjects were instructed to refrain from strenuous physical activity and to maintain their diet as constant as possible for 2 days prior to the experimental infusions. On the evening before the trial, the subjects consumed a standardized meal (2.38 MJ, 31.7 Ϯ 1.1 kJ/kg body wt) composed of 15 energy percent (en%) protein, 55 en% carbohydrate, and 30 en% fat.
Experimental protocol. At 0800, after an overnight fast, subjects arrived at the laboratory by car or public transport. Upon the subjects' arrival at the laboratory, a Teflon catheter was inserted into an antecubital vein for infusion and a second cannula was inserted into the dorsal hand vein of the contralateral arm, which was placed in a hot box (60°C) for arterialized blood sampling (1). After baseline blood collection (Ϫ210 min), the plasma phenylalanine, tyrosine, and leucine pools were primed with a single intravenous (priming) dose of Ϫ at 2 h prior to protein ingestion to ensure that the increase in NO 3 Ϫ /NO 2 Ϫ concentrations would correspond with the postprandial increase in plasma amino acid concentrations (58) . Blood samples were collected during the infusion at Ϫ120, Ϫ90, Ϫ60, Ϫ30, 0, 15, 30, 45, 60, 90, 120, 150, 180, 210, 240, 270, and 300 min relative to the intake of the protein drink. Blood samples were collected into EDTA-containing tubes and centrifuged at 1,000 g at 4°C for 10 min. Aliquots of plasma were frozen in liquid nitrogen and stored at Ϫ80°C. Muscle biopsies were collected for determination of postabsorptive muscle protein synthesis rates (Ϫ120 and 0 min). Immediately after the second biopsy, subjects ingested a single bolus of 20 g of intrinsically L- [1- 13 C]phenylalanine-and L-[1-
13 C]leucine-labeled casein protein dissolved in water that was flavored with 1.5 ml of vanilla (IMCD Benelux, Rotterdam, The Netherlands). Additional biopsies (from the contralateral leg) were collected at 120 and 300 min for measurement of postprandial muscle protein synthesis rates. The Bergström needle technique (5) was used to collect muscle biopsies from the middle region of the vastus lateralis (15 cm above the patella). All biopsy samples were freed from visible adipose tissue and blood, immediately frozen in liquid nitrogen, and stored at Ϫ80°C until subsequent analysis.
Production of intrinsically labeled protein. C]leucine (200 mol/min), collection of the milk, and purification of the casein fraction, as described previously (8, 36, 45) . Enrichments of L-[1- Plasma analyses. Plasma NO 3 Ϫ and NO 2 Ϫ were analyzed by gasphase chemiluminescence analysis, which has been described previously (12) . Briefly, plasma NO 3 Ϫ and NO 2 Ϫ concentrations are determined by their reduction to NO. The spectral emission of electronically excited nitrogen dioxide, from the NO reaction with ozone, is detected by a thermoelectrically cooled, red-sensitive photomultiplier 15 N]tyrosine were added to the samples, which were deproteinized on ice with dry 5-sulfosalicylic acid. Free amino acids were purified using cation-exchange chromatography (AG 50W-X8 resin, 100-to 200-m dry mesh; Bio-Rad Laboratories, Hercules, CA) and converted to their tert-butyl dimethylsilyl (t-BDMS) derivative before GC-MS analysis. The amino acid concentrations were determined using electron impact ionization by monitoring ions at mass-to-charge ratios (m/z) of 302 and 308 for unlabeled and [U-
13 C6]-labeled leucine, respectively, m/z 336 and 346 for unlabeled and [U-13 C9
15 N]-labeled phenylalanine, respectively, and m/z 466 and 476 for unlabeled and [U-13 C9
15 N]-labeled tyrosine, respectively. The plasma phenylalanine and tyrosine 13 C and 2 H enrichments were determined using selective ion monitoring at m/z 336, 337, and 341 for unlabeled and labeled (1-13 C and ring-2 H5) phenylalanine, respectively, and m/z 466, 467, 468, and 470 for unlabeled and labeled (1-13 C, ring-3,5-2 H2, and ring-2 H4) tyrosine, respectively. For L-[1-
13 C]leucine, m/z 302 (m ϩ 0) and m/z 303 (m ϩ 1) were monitored. Standard regression curves were applied from a series of known standard enrichment values against the measured values to assess the linearity of the mass spectrometer and to account for any isotope fractionation that may have occurred during the analysis. Phenylalanine and tyrosine enrichments were corrected for the presence of the 13 
C and 2 H isotopes. Plasma isotopic enrichment of the t-BDMS derivative of ␣-[
13 C]ketoisocaproate (KIC) was measured by GC-MS analysis for use as a surrogate for leucyl-tRNA labeling (52) .
Muscle analyses. The muscle intracellular free amino acids were extracted from ϳ50 mg of wet muscle tissue. The muscle was homogenized on ice with a Teflon-coated pestle using ice-cold 2% perchloric acid (7 l ϫ wet weight) and then centrifuged at 10,000 g and 4°C for 5 min. The supernatant was collected, and this process was repeated twice. The supernatant was taken as the muscle intracellular free amino acid pool and processed in the same manner as the plasma samples for isotopic enrichment by GC-MS analysis. Myofibrillar protein-enriched fractions were extracted from a separate ϳ50mg piece of wet muscle tissue by hand-homogenization on ice using a pestle (Teflon) in a standard extraction buffer (7.5 l/mg) (27) . The samples were spun at 1,500 g and 4°C for 10 min. The supernatants containing sarcoplasmic proteins were removed. The remaining myofibrillar and collagen pellets were washed with 500 l of extraction buffer and spun at 700 g and 4°C for 10 min. The myofibrillar protein was solubilized by addition of 1.5 ml of 0.3 M NaOH and heating at 50°C for 30 min, with vortex mixing every 10 min. Samples were centrifuged at 10,000 g and 4°C for 5 min, and the supernatant containing the myofibrillar-enriched fraction was collected and the collagen pellet was discarded. Myofibrillar proteins were precipitated by addition of 1 ml of 1 M perchloric acid and spinning at 700 g and 4°C for 10 min. The myofibrillar protein was washed twice with 70% ethanol. Amino acids were liberated by addition of 2 ml of 6 M HCl and heating at 110°C for 24 h. The hydrolyzed myofibrillar protein fraction was dried under a nitrogen stream while being heated to 120°C and, subsequently, dissolved in a 25% acetic acid solution and passed over a Dowex exchange resin (AG 50W-X8, 100-to 200-m mesh hydrogen form; Bio-Rad Laboratories). The free amino acids were eluted with 2 M NH4OH and dried, and the purified amino acids were derivatized into N-tertbutylmethylsilyl-N-methyltrifluoroacetamide-phenylethylamines (11, 38) for measurement of L-[ring-
2 H5]phenylalanine labeling using GC-MS analysis, as described previously (10) . To reduce the signalto-noise ratio during GC-MS analysis at low tracer enrichments, the phenylalanine from the myofibrillar protein hydrolysates was enzymatically decarboxylated to phenylethylamine (9) prior to t-BDMS derivatization (32, 33) . Enrichments of the protein-bound samples were determined by selected ion monitoring for phenylalanine m/z 183 (m ϩ 5) to m/z 180 (m ϩ 2) and a single linear standard curve (to avoid slope influences on the measured tracer-to-tracee ratio) from mixtures of known m ϩ 5 to m ϩ 0 ratios. To avoid saturation of the mass spectrometer and eliminate bias due to any potential concentration dependencies (22) , the split ratio was adjusted prior to the injection of each sample, so that nearly equal amounts of phenylalanine were injected for all samples and standards. ) and plasma phenylalanine availability [i.e., the fraction of dietary protein-derived phenylalanine that appeared in the systemic circulation (Pheplasma)] were calculated using modified Steele's equations (6, 16, 57) .
Total phenylalanine R a was calculated using Eq. 1, where Fiv is the intravenous tracer infusion rate (in mol·kg Ϫ1 ·min Ϫ1 ) and pV is the distribution volume for phenylalanine (0.125 l/kg) (6). C(t) is the mean plasma phenylalanine concentration between two consecutive time points, and dE iv/dt represents the time-dependent change in plasma phenylalanine enrichment derived from the intravenous tracer and E iv(t) is the mean plasma phenylalanine enrichment from the intravenous tracer between two consecutive time points.
Exogenous phenylalanine R a (Eq. 2; Exo Ra) represents the plasma entry rate of dietary protein-derived phenylalanine. Epo(t) is the mean plasma phenylalanine enrichment of the oral tracer, dEpo/dt represents the time-dependent change in plasma phenylalanine enrichment derived from the oral tracer, and E prot is the enrichment of L-[1- endogenous R a ϭ total R a Ϫ endogenous R a Ϫ F iv
Endogenous phenylalanine Ra (Eq. 3; Endo Ra) represents the plasma entry rate of phenylalanine derived from whole body protein breakdown.
Pheplasma was calculated using Eq. 4. AUCExoRa is the area under the curve (AUC) of Exo Ra, BW is the body weight of the subject (in kg), and Pheprot is the amount of dietary phenylalanine that is ingested.
Total phenylalanine rate of disappearance (Eq. 5; Rd, in mol Phe·kg Ϫ1 ·min Ϫ1 ) equals the rate of phenylalanine hydroxylation (the 1st step in phenylalanine oxidation) and utilization for protein synthesis. These parameters are calculated as follows
Phe hydroxylation ϭ Tyr R a · E tyr͑ t͒
protein synthesis ϭ total R d Ϫ Phe hydroxylation
Phe net balance ϭ protein synthesis Ϫ endogenous R a (8) Tyr Ra is the total rate of tyrosine appearance based on the 13 C]KIC enrichment during the tracer incorporation period (in MPE), and t is the incorporation period (in hours). For basal FSR, muscle biopsies at Ϫ120 and 0 min were used; for postprandial FSR, biopsies at 0, 120, and 300 min were used to calculate the early (0 -2 h) and late (2-5 h) postprandial muscle protein synthetic response.
Statistics. Values are means Ϯ SE. Differences in baseline values were determined using an unpaired, two-tailed Student's t-test. Incremental AUC (iAUC), peak value, and time to peak were calculated for all plasma time curves, and differences were determined using an unpaired, two-tailed Student's t-test. Two-way ANOVA with time as the within-group factor and intervention as the between-group factor was used to compare differences over time in plasma glucose, insulin, NO 3 Ϫ , NO 2 Ϫ , amino acid concentrations and enrichments, whole body phenylalanine Ra, and FSR. In case of significant interaction between time and intervention, Bonferroni's post hoc test was applied. Differences between intervention groups in muscle free and protein-bound amino acid enrichments were analyzed with an unpaired, two-tailed Student's t-test. For all analyses, statistical significance was set at P Ͻ 0.05. All calculations were performed using IBM SPSS Statistics (version 21).
RESULTS

Plasma analyses. Plasma NO 3
Ϫ and NO 2 Ϫ concentrations are presented in Fig. 1 . Plasma NO 3 Ϫ concentrations (Fig. 1A) did not differ at baseline (Ϫ210 min) between intervention groups and increased following NaNO 3 Ϫ ingestion (P Ͻ 0.001). Throughout the experiment, NO 3 Ϫ concentrations were significantly higher in the PRONO3 than the PRO group (P Ͻ 0.001, time ϫ intervention interaction P Ͻ 0.001, iAUC P Ͻ 0.001), reaching peak values of 663 Ϯ 22 and 39 Ϯ 2 mol/l in the PRONO3 and PRO groups, respectively (P Ͻ 0.001). Plasma NO 2 Ϫ concentrations (Fig. 1B) increased significantly following NaNO 3 Ϫ ingestion in the PRONO3 group only (time effect P Ͻ 0.01, group effect P Ͻ 0.05, time ϫ intervention interaction P Ͻ 0.01), reaching peak values of 788 Ϯ 138 and 389 Ϯ 55 mmol/l in the PRONO3 and PRO groups, respectively (peak values P Ͻ 0.05, iAUC P Ͻ 0.01).
Plasma glucose and insulin concentrations are shown in Fig.  2 . Plasma glucose concentrations ( Fig. 2A) did not differ between interventions throughout the experimental trial. Plasma insulin concentrations (Fig. 2B) increased following protein ingestion (P Ͻ 0.001), but to a greater extent in the PRO than the PRONO3 group (time ϫ intervention interaction P Ͻ 0.001, iAUC P ϭ 0.4).
Plasma amino acid concentrations (Fig. 3) increased after protein ingestion (P Ͻ 0.001), with no differences between groups for phenylalanine (Fig. 3A) and leucine (Fig. 3C) concentrations. Plasma tyrosine concentrations (Fig. 3B) were higher in the PRO group during the postprandial period (intervention effect P Ͻ 0.05, iAUC P ϭ 0.3).
Plasma amino acid enrichments are presented in Fig. 4 . Plasma L-[ring-2 H 5 ]phenylalanine (Fig. 4A ) and L-[1-13 C]leucine (Fig. 4C ) enrichments did not differ between interventions in the basal and postprandial periods. Plasma L-[1-
13 C]phenylalanine enrichments (Fig. 4B) increased following protein ingestion in both intervention groups (P Ͻ 0.001), reaching peak values of 12.3 Ϯ 0.7 MPE at 72 Ϯ 12 min and 11.8 Ϯ 0.8 MPE at 86 Ϯ 24 min in the PRO and PRONO3 groups, respectively, and did not differ between groups (intervention effect P ϭ 0.7, iAUC P ϭ 0.8).
Whole body phenylalanine kinetics. Whole body phenylalanine R a values are presented in Fig. 5 . Exogenous phenylalanine R a (Fig. 5A ) increased rapidly following protein ingestion (P Ͻ 0.001) and did not differ between groups. The fraction of dietary protein-derived phenylalanine that was released in the plasma over the 5h postprandial period was 55 Ϯ 2% and 53 Ϯ 2% in the PRO and PRONO3 groups, respectively. Endogenous phenylalanine R a (Fig. 5B) decreased following protein ingestion and did not differ between intervention groups. No differences were detected between interventions in total plasma phenylalanine R a (Fig. 5C ) and R d (Fig. 5D ).
Postabsorptive and postprandial whole body protein breakdown, synthesis, oxidation, and net balance are presented in Fig. 6 . Whole body protein breakdown rates decreased following protein ingestion (P Ͻ 0.001). Whole body protein synthesis rates increased after protein ingestion (P Ͻ 0.001), with no differences between groups (P ϭ 0.3). Whole body protein oxidation rates were significantly higher in the PRO than the PRONO3 group in the basal and postprandial periods (P Ͻ 0.05). Whole body protein net balance in the postabsorptive phase was significantly higher in the PRONO3 than the PRO group (0.66 Ϯ 0.10 vs. 1.04 Ϯ 0.12 mol·kg·h Ϫ1 , P Ͻ 0.05) and increased in the postprandial phase (7.71 Ϯ 0.33 and 7.80 Ϯ 0.53 mol·kg·h Ϫ1 in PRO and PRONO3, respectively, P Ͻ 0.001), with no differences between groups (P ϭ 0.8).
Muscle protein synthesis. Myofibrillar protein synthesis rates, expressed as FSR, are presented in Fig. 7 . Postabsorptive myofibrillar FSR based on the L-[ring-2 H 5 ]phenylalanine tracer (Fig. 7A) , with plasma L-[ring-2 H 5 ]phenylalanine enrichments used as precursor pool, did not differ between interventions (P ϭ 0.6). After protein ingestion, myofibrillar protein synthesis rates in the PRO and PRONO3 groups averaged 0.025 Ϯ (Fig. 7B) , with plasma ␣-[1-
13 C]KIC enrichments used as precursor pool, did not differ between groups (P ϭ 0.8). After protein ingestion, early and late postprandial muscle protein synthesis rates in PRO and PRONO3 groups averaged 0.039 Ϯ 0.007 and 0.040 Ϯ 0.011%/h and 0.046 Ϯ 0.008 and 0.038 Ϯ 0.007%/h, respectively, with no differences between groups (time effect P ϭ 0.7, intervention effect P ϭ 0.7). Myofibrillar protein-bound L-[1-
13 C]phenylalanine enrichments in PRO and PRONO3 groups averaged 0.0051 Ϯ 0.0011 and 0.0061 Ϯ 0.0013 MPE, respectively, at 2 h and 0.0155 Ϯ 0.0020 and 0.0135 Ϯ 0.0022 MPE, respectively, at 5 h, with no differences between groups (time effect P Ͻ 0.001, intervention effect P ϭ 0.8).
Muscle tissue free L-[ring-2 H 5 ]phenylalanine, L-[1-13 C]leucine, and L-[1-
13 C]phenylalanine enrichments did not differ between groups (Table 2 ). Similar observations were observed when myofibrillar protein synthesis rates were calculated based on use of muscle free phenylalanine enrichments as precursor pool (data not shown).
DISCUSSION
This is the first study to assess if a single dose of dietary NO 3 Ϫ ingested with protein increases amino acid delivery to skeletal muscle tissue and, subsequently, augments the postprandial muscle protein synthetic response in older, type 2 diabetes patients. The ingestion of 20 g of protein increased plasma amino acid availability (Figs. 3-5) , stimulated whole body protein synthesis (Fig. 6) , increased myofibrillar protein synthesis rates (Fig. 7) , and enhanced the use of dietary protein-derived amino acids for de novo muscle protein synthesis (Fig. 8) . However, co-ingestion of a single dose of dietary NO 3 Ϫ with the same amount of protein did not modulate postprandial protein handling in older men with type 2 diabetes.
Reductions in vascular function in response to aging and/or diabetes may be due in part to reductions in NO synthesis and a reduced NO-mediated vasodilatory response to feeding-induced hyperinsulinemia (24) . Consequently, a reduction in NO-mediated vascular function may attenuate postprandial plasma amino acid delivery to tissues, thereby having a negative impact on normal feeding-mediated increases in postprandial muscle protein synthesis rates. Current evidence suggests that the ingestion of dietary NO 3 Ϫ can substantially increase NO availability, which may be of particular importance in pathological conditions associated with a disrupted NO synthase (NOS)-NO pathway, as in the case of aging or diabetes (22, 54) . Inorganic NO 3 Ϫ is converted to NO 2 Ϫ by NO 3 Ϫ reductase-expressing bacteria, which naturally reside in the oral cavity. Once salivary NO 2 Ϫ is swallowed, some of it enters the systemic circulation, where it is chemically reduced to NO. A recent study by Wylie and co-workers (58) showed that changes in plasma NO 2 Ϫ occur 2-3 h after ingestion of beetroot juice (a concentrated source of dietary NO 3 Ϫ ). Therefore, we provided a single dose of dietary NO 3 Ϫ at 2 h prior to protein ingestion, so that increased NO 2 Ϫ concentrations would temporally correspond with increased postprandial plasma amino acid concentrations. The ingestion of NaNO 3 Ϫ increased plasma NO 3 Ϫ concentrations, which remained elevated for up to 7 h (Fig. 1) . Moreover, plasma NO 2 Ϫ increased following the ingestion of NaNO 3 Ϫ , reaching peak concentrations of ϳ800 mmol/l at 30 min after protein ingestion. These findings indicate an intact enterosalivary circuit in older, type 2 diabetes patients. After protein ingestion, plasma amino acid concentrations increased in both groups (Fig. 3) . By combining the ingestion of intrinsically L-[1-
13 C]phenylalanine-labeled protein with a primed continuous L-[ring- 2 H 5 ]phenylalanine infusion, we were able to measure protein-derived L-[1-
13 C]phenylalanine enrichments (Fig. 4) and quantify the R a of dietary proteinderived amino acids into the circulation (Fig. 5) (8, 45) . Plasma L-[1-
13 C]phenylalanine enrichments increased directly following protein ingestion in both groups, reaching peak values of 12.3 Ϯ 0.7 and 11.8 Ϯ 0.8 MPE in the PRO and PRONO3 groups, respectively. In total, 55 Ϯ 2% and 53 Ϯ 2% of the ingested protein became available in the circulation during the 5-h postprandial period in the PRO and PRONO3 groups, respectively. Despite previous reports that dietary strategies augmenting NO metabolism may alter gut and organ tissue perfusion (47, 56) , the greater plasma NO 2 Ϫ availability in the PRONO3 group did not modulate dietary protein digestion, amino acid absorption, or the amount of protein-derived amino acids that became available within the circulation after the ingestion of 20 g of protein in these older, type 2 diabetes patients.
Protein ingestion increased postprandial whole body protein synthesis and decreased whole body protein breakdown rates, resulting in a positive postprandial whole body protein net balance. However, ingestion of dietary NO 3 Ϫ did not modulate postprandial whole body protein turnover rates (Fig. 6) . Our results seem to agree with previous observations by Thibault and colleagues (42) , who were unable to detect an effect of citrulline, a substrate for NOS-mediated NO synthesis, on whole body protein turnover. In addition to measuring whole body protein turnover rates, we also measured the impact of dietary NO 3 Ϫ ingestion on the postprandial myofibrillar protein synthetic response. The ingestion of a meallike amount of protein increased postprandial myofibrillar protein synthesis rates; however, co-ingestion of dietary NO 3 Ϫ did not further increase postprandial myofibrillar protein synthesis rates (Fig. 7) . In addition to determining the postprandial myofibrillar protein synthesis rates, we used highly enriched (38.7 MPE) , intrinsically L-[1-
13 C]phenylalanine-labeled protein to assess the metabolic fate of the ingested protein by measuring the incorporation of dietary Ϫ . Values are means Ϯ SE. Data were analyzed with unpaired Student's t-test (between groups) and repeated-measures (time ϫ intervention) ANOVA. Whole body protein breakdown rates: time effect P Ͻ 0.001; whole body protein synthesis rates: time effect P Ͻ 0.001; whole body protein oxidation rates: time effect P Ͻ 0.001, basal between-groups P ϭ 0.01, postprandial between-groups P ϭ 0.04; whole body protein net balance: time effect P Ͻ 0.001, basal between-groups P ϭ 0.02. *Significant time effect, P Ͻ 0.01. #Significant difference between groups, P Ͻ 0.05.
protein-derived L-[1-
13 C]phenylalanine into de novo muscle tissue (Fig. 8) . Protein ingestion resulted in a substantial increase in myofibrillar protein-bound L-[1-
13 C]phenylalanine enrichments at 2 and 5 h, but no additional effect of dietary NO 3 Ϫ co-ingestion was observed.
Reductions in NO synthesis in older adults may be partly responsible for diminished NO-mediated capillary recruitment and the blunted muscle protein synthetic response to the postprandial rise in plasma amino acid concentrations. In support of this notion, pharmacological strategies utilizing NO donors (i.e., sodium nitroprusside or methacholine) have been shown to effectively increase blood flow and microvascular perfusion and augment the muscle protein synthetic response to amino acid administration (17, 44) . However, practical dietary interventions providing precursors for endothelial NOS-mediated NO synthesis, such as citrulline (13) and/or arginine (41) co-ingested with protein, have not been effective in increasing the postprandial rise in muscle protein synthesis rates. In the present study, dietary NO 3 Ϫ was provided as a practical nutritional strategy to increase NO availability through a separate pathway that does not require endothelial NOS. Supplementation of dietary NO 3 Ϫ has been shown to have significant effects on endothelial function (21), blood pressure (4, 53, 58) , and O 2 consumption during exercise (58) in young and older subjects. However, despite the established effects of NO 3 Ϫ on vascular function, our results demonstrate that co-ingestion of NO 3 Ϫ with a meal-like amount of protein does not augment postprandial plasma amino acid availability, modulate whole body protein metabolism, increase skeletal muscle protein synthesis rates, or stimulate incorporation of dietary protein-derived amino acids into de novo myofibrillar protein. These data are the first to demonstrate that acute NO 3 Ϫ supplementation does not represent an effective nutritional strategy to enhance postprandial protein handling in vivo in humans. As acute dietary interventions to restore vascular function do not appear to increase postprandial muscle protein synthesis rates (13, 37, 41) , longer-term intervention studies involving chronic supplementation of NO substrates may be necessary to enhance vascular function and augment the anabolic response to protein ingestion (30, 48, 59 
